SEARCH

SEARCH BY CITATION

References

  • Annoni, A., Brown, B.D., Cantore, A., Sergi, L.S., Naldini, L. & Roncarolo, M.G. (2009) In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood, 114, 51525161.
  • Avalos, A.M., Busconi, L. & Marshak-Rothstein, A. (2010) Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity, 43, 7683.
  • Battaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T. & Roncarolo, M.G. (2006) Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. Journal of Immunology, 177, 83388347.
  • Belay, E., Mátrai, J., Acosta-Sanchez, A., Ma, L., Quattrocelli, M., Mátés, L., Sancho-Bru, P., Geraerts, M., Yan, B., Vermeesch, J., Rincón, M.Y., Samara-Kuko, E., Ivics, Z., Verfaillie, C., Sampaolesi, M., Izsvák, Z., Vandendriessche, T. & Chuah, M.K. (2010) Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. Stem Cells, 28, 17601771.
  • Bergamaschini, L., Santangelo, T., Faricciotti, A., Ciavarella, N., Mannucci, P. & Agostoni, A. (1996) Study of complement-mediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and/or lgG4) in the complement-activating capacity of immune complexes. Journal of Immunology, 156, 12561261.
  • Brackmann, H.H., Oldenburg, J. & Schwaab, R. (1996) Immune tolerance for the treatment of F8 inhibitors – twenty years ‘Bonn Protocol’. Vox Sanguinis, 70(Suppl. 1), 3035.
  • Callaghan, M.U., Rajpurkar, M., Chitlur, M., Warrier, I. & Lusher, J. (2011) Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? Haemophilia, 17, 483489.
  • Calne, R.Y., Sells, R.A., Pena, R.J., Davis, D.R., Millard, P.R., Herbertson, P.M., Binns, R.M. & Davies, D.A. (1969) Induction of immunological tolerance by porcine liver allografts. Nature, 223, 472476.
  • Cao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C. & Herzog, R.W. (2007) Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood, 110, 11321140.
  • Cao, O., Hoffman, B.E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H.C., High, K.A. & Herzog, R.W. (2009) Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Molecular Therapy, 17, 17331742.
  • Chang, A.H., Stephan, M.T. & Sadelain, M. (2006) Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nature Biotechnology, 24, 10171021.
  • Chang, A.H., Stephan, M.T., Lisowski, L. & Sadelain, M.. (2008) Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Molecular Therapy, 16, 17451752.
  • Check, E. (2005) Gene therapists urged to learn more immunology (News and views). Nature, 434, 812.
  • Chuah, M.K., Vandendriessche, T. & Morgan, R.A. (1995) Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Human Gene Therapy, 6, 13631377.
  • Chuah, M.K., Collen, D. & VandenDriessche, T. (2004) Clinical gene transfer studies for hemophilia A. Seminars in Thrombosis and Hemostasis, 30, 249256.
  • Constantinescu, A.R., Weiss, L.S., Saidi, P., Eisele, J. & Ettinger, L.J. (1997) Nephrotic syndrome associated with hypocomplementemia in a 4-year-old boy with hemophilia B. Journal of Pediatric Hematology/oncology, 19, 345347.
  • Coppola, A., Di Capua, M. & De Simone, C. (2008) Primary prophylaxis in children with haemophilia. Blood Transfusion, 6(Suppl. 2), s4s11.
  • Dave, U.P., Copeland, N.A. & Copeland, N.G. (2004) Gene therapy insertional mutagenesis insights. Science, 303, 333.
  • David, A.L., McIntosh, J., Peebles, D.M., Cook, T., Waddington, S., Weisz, B., Wigley, V., Abi-Nader, K., Boyd, M., Davidoff, A.M. & Nathwani, A.C. (2011) Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep. Human Gene Therapy, 22, 419426.
  • De Groot, A.S., Moise, L., McMurry, J.A., Wambre, E., Van Overtvelt, L., Moingeon, P., Scott, D.W. & Martin, W. (2008) Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes.” Blood, 112, 33033311.
  • Di Michele, D.M. (2011) Immune tolerance induction in haemophilia: evidence and the way forward. Journal of Thrombosis and Haemostasis, 9(Suppl. 1), 216225.
  • Doering, C.B., Archer, D. & Spencer, H.T. (2010) Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells. Advanced Drug Delivery Reviews, 62, 12041212.
  • Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Güngör, T., Krackhardt, B. & Kornhuber, B. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 594598.
  • Evans, G.L. & Morgan, R.A. (1998) Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proceedings of the National Academy of Sciences of the United States of America, 95, 57345739.
  • Ewenstein, B.M., Takemoto, C., Warrier, I., Lusher, J., Saidi, P., Eisele, J., Ettinger, L.J. & DiMichele, D. (1997) Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood, 89, 11151116.
  • Finn, J.D., Hui, D., Downey, H.D., Dunn, D., Pien, G.C., Mingozzi, F., Zhou, S. & High, K.A. (2009) Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Molecular Therapy, 18, 135142.
  • Finn, J.D., Ozelo, M.C., Sabatino, D.E., Franck, H.W., Merricks, E.P., Crudele, J.M., Zhou, S., Kazazian, H.H., Lillicrap, D., Nichols, T.C. & Arruda, V.R. (2010) Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood, 116, 58425848.
  • Fischer, A., Hacein-Bey-Abina, S. & Cavazzano-Calvo, M. (2010) 20 years of gene therapy for SCID. Nature Immunology, 11, 457460.
  • Fulcher, C.A., de Graaf, M.S. & Zimmerman, T.S. (1987) F8 inhibitor IgG subclass and F8 polypeptide specificity determined by immunoblotting. Blood, 69, 14751480.
  • Gao, G.P., Alvira, M.R., Wang, L., Calcedo, R., Johnston, J. & Wilson, J.M. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 99, 1185411859.
  • Gewirtz, J., Thornton, M.A., Rauova, L. & Poncz, M. (2008) Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. Journal of Thrombosis and Haemostasis, 6, 11601166.
  • Hacein-Bey-Abina, S., Hauer, J., Lim, A., Picard, C., Wang, G.P., Berry, C.C., Martinache, C., Rieux-Laucat, F., Latour, S., Belohradsky, B.H., Leiva, L., Sorensen, R., Debré, M., Casanova, J.L., Blanche, S., Durandy, A., Bushman, F.D., Fischer, A. & Cavazzana-Calvo, M. (2010) Efficacy of gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine, 363, 355364.
  • High, K.A. (2011) Gene therapy for haemophilia: a long and winding road. Journal of Thrombosis and Haemostasis, 9(Suppl. 1), 211.
  • Hough, C. & Lillicrap, D. (2005) Gene therapy for hemophilia: an imperative to succeed. Journal of Thrombosis and Haemostasis, 3, 11951205.
  • Hoyer, L.W. (1994) Hemophilia A. New England Journal of Medicine, 330, 3847.
  • Jacquemin, M., Neyrinck, A., Hermanns, M.I., Lavend’homme, R., Rega, F., Saint-Remy, J.-M., Peerlinck, K., Van Raemdonck, D. & Kirkpatrick, C.J. (2006) F8 production by human lung microvascular endothelial cells. Blood, 108, 515517.
  • Jadhav, M. & Warrier, I. (2000) Anaphylaxis in patients with hemophilia. Seminars in Thrombosis and Hemostasis, 26, 205208.
  • Jiang, H., Lillicrap, D., Patarroyo-White, S., Liu, T., Qian, X., Scallan, C.D., Powell, S., Keller, T., McMurray, M., Labelle, A., Nagy, D., Vargas, J.A., Zhou, S., Couto, L.B. & Pierce, G.F. (2006) Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood, 108, 33213328.
  • Kasper, C.K. (1991) Complications of hemophilia A treatment: factor VIII inhibitors. Annals of the New York Academy of Sciences, 614, 97105.
  • Kay, M. (2011) State –of-the-art gene-based therapies: the road ahead. Nature reviews. Genetics, 12, 316328.
  • Kurnik, K., Bidlingmaier, C., Engl, W., Chehadeh, H., Reipert, B. & Auerswald, G. (2010) New early prophylaxis regimen that avoids immunological danger signals can reduce F8 inhibitor development. Haemophilia, 16, 256262.
  • Lei, T.-C. & Scott, D.W. (2005) Induction of tolerance to F8 inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B-cells as Ig fusion proteins. Blood, 105, 48654870.
  • Liu, C.L., Ye, P., Yen, B.C. & Miao, C.H. (2011) In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Molecular Therapy, 19, 15111520.
  • Manco-Johnson, M.J., Abshire, T.C., Shapiro, A.D., Riske, B., Hacker, M.R., Kilcoyne, R., Ingram, J.D., Manco-Johnson, M.L., Funk, S., Jacobson, L., Valentino, L.A., Hoots, W.K., Buchanan, G.R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G.A., Thompson, A.A., McRedmond, K., Soucie, J.M., Austin, H. & Evatt, B.L. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. New England Journal of Medicine, 357(6), 535544.
  • Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P.K., Nakai, H., Chew, A., Leonard, D., Wright, J.F., Lessard, R.R., Sommer, J.M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H.C., High, K.A. & Kay, M.A. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 12, 342347.
  • Mannucci, P.M. & Tuddenham, E.G. (2001) The hemophilias – from royal genes to gene therapy. New England Journal of Medicine, 344, 17731779.
  • Matsui, H., Shibata, M., Brown, B., Labelle, A., Hegadorn, C., Andrews, C., Chuah, M., VandenDriessche, T., Miao, C.H., Hough, C. & Lillicrap, D. (2009) A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells. Blood, 114, 677685.
  • Matsui, H., Hegadorn, C., Ozelo, M., Burnett, E., Tuttle, A., Labelle, A., McCray, Jr, P.B., Naldini, L., Brown, B., Hough, C. & Lillicrap, D. (2011) A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of F8 in a murine model of hemophilia A. Molecular Therapy, 19, 723730.
  • Mauri, C. (2010) Regulation of immunity and autoimmunity by B cells. Current Opinion in Immunology, 22, 761767.
  • Miao, C.H. (2010) Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Review of Hematology, 3, 469483.
  • Miao, C.H., Ye, P., Thompson, A.R., Rawlings, D.J. & Ochs, H.D. (2006) Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood, 108, 1927.
  • Mingozzi, F. & High, K.A. (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature reviews. Genetics, 12, 341355.
  • Mingozzi, F., Liu, Y.L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A. & Herzog, R.W. (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. Journal of Clinical Investigation, 111, 13471356.
  • Mingozzi, F., Hasbrouck, N.C., Basner-Tschakarjan, E., Edmonson, S.A., Hui, D.J., Sabatino, D.E., Zhou, S., Wright, J.F., Jiang, H., Pierce, G.F., Arruda, V.R. & High, K.A. (2007) Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 110, 23342341.
  • Moayeri, M., Ramezani, A., Morgan, R.A., Hawley, T.S. & Hawley, R.G. (2004) Sustained phenotypic correction of hemophilia A mice following oncoretroviral-mediated expression of a ioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Molecular Therapy, 10, 892902.
  • Moayeri, M., Hawley, T.S. & Hawley, R.G. (2005) Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Molecular Therapy, 12, 10341042.
  • Naldini, L. (2011) Ex vivo gene transfer and correction for cell-based therapies. Nature reviews. Genetics, 12, 301315.
  • Nathwani, A.C., Rosales, C., McIntosh, J., Rastegarlar, J.G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S.N., Bronson, R., Jackson, S., Donahue, R.E., High, K.A., Mingozzi, F., Ng, C.Y., Zhou, J., Spence, Y., McCarville, M.B., Valentine, M., Allay, J., Coleman, J., Sleep, S., Gray, J.T., Nienhuis, A.W. & Davidoff, A.M. (2011a) Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human F9 pseudotyped with serotype 5 and 8 capsid proteins. Molecular Therapy, 19, 876885.
  • Nathwani, A.C., Tuddenham, E.G.D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, J., Harrington, C., Glader, B., Rustagi, P., Ng, C.Y.C., Kay, M.A., Zhou, J., Spence, Y., Morton, C.L., Allay, J., Coleman, J., Sleep, S., High, K.A., Mingozzi, F., Gray, J.T., Reiss, U.M., Nienhuis, A.W. & Davidoff, A.M. (2011b) Adeno-associated viral vector mediated gene transfer for hemophilia B. New England Journal of Medicine, 365, in press.
  • Navarrete, A.M., Dasgupta, S., Teyssandier, M., Repesse, Y., Delignat, S., André, S., Bayry, J., Kaveri, S.V. & Lacroix-Desmazes, S. (2010) Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation. Thrombosis and Haemostasis, 104, 10931098.
  • Nayak, S. & Herzog, R.W. (2010) Progress and prospects: immune responses to viral vectors. Gene Therapy, 17, 295304.
  • Nayak, S., Cao, O., Hoffman, B.E., Cooper, M., Zhou, S., Atkinson, M.A. & Herzog, R.W. (2009) Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. Journal of Thrombosis and Haemostasis, 7, 15231532.
  • Oberg, H.H., Juricke, M., Kabelitz, D. & Wesch, D. (2011) Regulation of T cell activation by TLR ligands. European Journal of Cell Biology, 90, 582592.
  • Oldenburg, J. (2011) Prophylaxis in bleeding disorders. Thrombosis Research, 127(Suppl. 1), S1417.
  • Peng, B., Ye, P., Blazar, B.R., Freeman, G.J., Rawlings, D.J., Ochs, H.D. & Miao, C.H. (2008) Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into haemophilia A mice. Blood, 112, 16621672.
  • Ponder, K.P. (2011) Hemophilia gene therapy: a holy grail found. Molecular Therapy, 19, 427428.
  • Powell, J.S., Ragni, M.V., White, II, G.C., Lusher, J.M., Hillman-Wiseman, C., Moon, T.E., Cole, V., Ramanathan-Girish, S., Roehl, H., Sajjadi, N., Jolly, D.J. & Hurst, D. (2003) Phase 1 trial of F8 gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood, 102, 20382045.
  • Qadura, M., Othman, M., Waters, B., Chegeni, R., Walker, K., Labelle, A., Ozelo, M., Hough, C. & Lillicrap, D. (2008) Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. Journal of Thrombosis and Haemostasis, 6, 20952104.
  • Rabinowitz, J.E., Bowles, D.E., Faust, S.M., Ledford, J.G., Cunningham, S.E. & Samulski, R.J. (2004) Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. Journal of Virology, 78, 44214432.
  • Ramezani, A. & Hawley, R.G. (2009) Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector. Blood, 114, 526534.
  • Roelse, J.C., De Laaf, R.T., Timmermans, S.M., Peters, M., Van Mourik, J.A. & Voorberg, J. (2000) Intracellular accumulation of factor VIII induced by missense mutations Arg593 – >Cys and Asn618 – >Ser explains cross-reacting material-reduced haemophilia A. British Journal of Haematology, 108, 241246.
  • Sabatino, D.E., Lange, A.M., Altynova, E.S., Sarkar, R., Zhou, S., Merricks, E.P., Franck, H.G., Nichols, T.C., Arruda, V.R. & Kazazian, Jr, H.H. (2011) Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Molecular Therapy, 19, 442449.
  • Scott, D.W. (1994) The Nature of Immunologic Tolerance. R.G. Landes Publishing, Austin, pp. 112.
  • Shi, Q., Wilcox, D.A., Fahs, S.A., Weiler, H., Wells, C.W., Cooley, B.C., Desai, D., Morateck, P.A., Gorski, J. & Montgomery, R.R. (2006) Factor VIII ectopically targeted to platelets is therapeutic in haemophilia A with high-titer inhibitory antibodies. Journal of Clinical Investigation, 116, 19741982.
  • Shi, Q., Fahs, S.A., Wilcox, D.A., Kuether, E.L., Morateck, P.A., Mareno, N., Weiler, H. & Montgomery, R.R. (2008) Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores haemostasis to haemophilia A mice with preexisting F8 immunity. Blood, 112, 27132721.
  • Skupsky, J., Zhang, A.H., Su, Y. & Scott, D.W. (2009) A role for thrombin in the initiation of the immune response to therapeutic Factor VIII. Blood, 114, 47414748.
  • Skupsky, J., Zhang, A.H., Su, Y. & Scott, D.W. (2010) B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Molecular Therapy, 18, 15271535.
  • Summers, R.J., Meeks, S.L., Healey, J.F., Brown, H.C., Parker, E.T., Kempton, C.L., Doering, C.B. & Lollar, P. (2011) Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein. Blood, 117, 31903198.
  • Tiegs, G. & Lohse, A.W. (2010) Immunologic tolerance: what is unique about the liver. Journal of Autoimmunity, 34, 16.
  • Vilaysane, A. & Muruve, D.A. (2009) The innate immune response to DNA. Seminars in Immunology, 21, 208214.
  • Voorberg, J., de Laaf, R.T., Koster, P.M. & van Mourik, J.A. (1996) Intracellular retention of a factor VIII protein with an Arg2307 – >Gln mutation as a cause of haemophilia A. Biochemical Journal, 15, 931937.
  • Warrier, I., Baird-Cox, K. & Lusher, J.M. (1997) Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience. Haemophilia, 3, 194198.
  • Waters, B., Qadura, M., Burnett, E., Chegeni, R., Labelle, A., Thompson, P., Hough, C. & Lillicrap, D.. (2009) Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood, 113, 193203.
  • Xu, L., Mei, M., Ma, X. & Ponder, K.P. (2007) High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice. Journal of Thrombosis and Haemostasis, 5, 18051812.
  • Yarovoi, H.V., Kufrin, D., Eslin, D.E., Thornton, M.A., Haberichter, S.L., Shi, Q., Zhu, H., Camire, R., Fakharzadeh, S.S., Kowalska, M.A., Wilcox, D.A., Sachais, B.S., Montgomery, R.R. & Poncz, M. (2003) Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood, 102, 40064013.
  • Zhang, A.H., Skupsky, J. & Scott, D.W. (2009) Factor VIII inhibitors: risk factors and methods for prevention and immune modulation. Clinical Reviews in Allergy and Immunology, 37, 114124.
  • Zhang, A.H., Skupsky, J. & Scott, D.W. (2011) Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human F8 in hemophilia A mice. Blood, 117, 22232226.